Faculty

Unbiased genomic- or proteomic-scale screens; mechanistic followup in relevant systems including neuronal culture and in vivo animal models

Translating genetics findings for human neurodegenerative disorders into molecular mechanisms of disease. We use chromatin conformation capture, epigenomics and bioinformatics techniques to identify actionable target genes in human iPSC-derived neural cell models.

Health economics and gene-environment interaction analysis of Alzheimer’s disease

Dr. Chow is an industry physician with extensive experience in clinical research in academic behavioral neuroscience elucidating the neurobiology of Alzheimer’s and other dementias, applying radioligand PET imaging and functional neuroimaging methods, neuropsychiatric assessments, and qualitative work to report on caregiver needs for education and support. She has been a thought leader in frontotemporal dementias, Alzheimer’s disease clinical trial design, and caregiver advocacy in cognitive disorders through career-long networking. She is the Clinical Core Lead for the NIA-funded Asian Cohort in Alzheimer’s Disease study.

Biomedical Image Analysis, Machine learning in Imaging, Imaging Biomarkers of Neurologic and Neuropsychiatric Diseases.

We are developing new tools to profile genome, epigenome, transcriptome, and proteome within the spatial context of tissues and cells. These novel technologies will greatly improve our ability to study tissue complexity and reveal the salient features of tissue architecture in physiology and disease.

Disease genomics, with a specific focus on pediatrics. High-throughput genotyping and sequencing technologies, combined with statistical and bioinformatic approaches.

Underlying pathology and genetics of neurodegenerative dementias, biomarkers.

I lead a broad research program in developing statistical methods and computational tools to address cutting-edge problems in public health by integrating large-scale, multi-source datasets. My lab has been developing powerful methods for multi-modal risk model development to characterize and understand health disparities and improve health outcomes for underrepresented minority populations. Our endeavors in the field have been reflected in our involvement in building risk models based on genetic, behavioral, and sociodemographic factors, which has led to insights into nephrology, mental health, and COVID-19.

Molecular biology of aging, cell senescence, Werner syndrome, telomeres, recombination, G-quadruplexes, neurodegeneration, transplantation.

We develop novel micro and nanotechnologies using bioengineering, molecular biology, and chemistry tools to address currently intractable diagnostic challenges for precision medicine.

Molecular pathways associated with neuropathologic inclusions in amyotrophic lateral sclerosis and frontotemporal lobar dementia.

Biology of tau, synucleins, TDP-43 and amyloid beta precursor proteins (APPs) in health and disease.

Computational biology and bioinformatics; software and algorithm development for large-scale genomic data analysis; copy number variation and structural variant detection.

small RNA and proteomic biomarkers for Alzheimer's disease and related dementias, genomic annotation and sequencing pipelines for Alzheimer's disease, RNA-seq bioinformatics

Statistical genetics, bioinformatics and computational biology for high-throughput genetics/genomics data; single-cell sequencing analysis.

Population genetics, human evolution and the genetics of complex traits

Neurodegeneration, Neuroimaging, Biomarkers, Frontotemporal Degeneration (FTD), Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS)

Genetic epidemiology for Alzheimer’s disease (AD) and other neurodegenerative diseases.

3D genome folding; Neurodevelopment; Neurodegenerative disease; Trinucleotide repeat expansion disorders; Epigenetics; Genomics

Computational biology and bioinformatics; genomics databases; ontology.

Statistical methods for genetic and genomic studies; bioinformatics.

Genetics of neurodegenerative diseases, in particular frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).

Statistical genetics, computational biology, and population genetics-based approaches to understand the biological underpinnings and evolutionary history of human phenotypes.